Fulcrum Therapeutics Inc (FULC) Stock Price, Quote & News

Company Profile

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Fa...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 651 8851

Website: www.fulcrumtx.com

Address:

26 Landsdowne Street, Cambridge, United States

Zackpedia Jun. 10 at 3:55 PM

$FULC Down to 3.36 now, you could’ve sold when I alerted and bought back now if you wanted.

0 · Reply

Zackpedia Jun. 10 at 2:29 PM

$FULC 3.56 again!

0 · Reply

zerodayrounder Jun. 10 at 2:05 PM

$FULC someone taking small shot on July 4c? What if they already identified a reverse merge partner?

0 · Reply

Zackpedia Jun. 10 at 9:20 AM

$FULC Down to 3.38 now, you could’ve sold when I alerted and bought back now if you wanted.

1 · Reply

Zackpedia Jun. 9 at 7:39 PM

$FULC And we’re up it’s 3.58 now!

0 · Reply

Zackpedia Jun. 9 at 2:16 PM

$FULC You could’ve sold at 3.6 today!

0 · Reply

Zackpedia Jun. 8 at 7:32 PM

$FULC Down to 3.36 now where you can buy back if you want, you could’ve sold when I alerted

0 · Reply

AXLFI_HQ Jun. 7 at 4:05 PM

$FULC Biotechnology companies face clinical development setbacks and regulatory pathway challenges, forcing workforce reductions and strategic alternatives reviews. Learn more: https://axlfi.com/themes/341

0 · Reply

StockScanners Jun. 6 at 10:54 PM

$FULC 3.50 is the area that stands out on this chart. What makes it interesting is the amount of overhead space that begins to open up beyond that level. Markets often become more dynamic when price approaches areas where prior trading activity has been limited. The relationship between 3.50 and the nearby gap structure is what has my attention. Curious whether others are viewing the chart through a similar lens or focusing on a different level altogether.

0 · Reply

zerodayrounder Jun. 6 at 3:04 AM

$SPRO dang $FULC cut 85% of employees and down to 9 FTEs. Incurred 4.2 million charge. Burn rate probably coming down from 22 million / qtr to like 6-7 million. FULC prob a better reverse merge shell than SPRO now $330 million cash as of Q1 and hired Leerink to help with strat alts Tick tock Spero ... monetize tebi and lock in Immunitas. LFG already

1 · Reply

Fulcrum Therapeutics downgraded to Underweight from Overweight at JPMorgan

2026-06-02T20:18:59.000Z - 7 days ago

Goldman suspends rating on Fulcrum Therapeutics

Jun 2, 2026, 12:56 PM EDT - 8 days ago

Fulcrum Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses

2026-06-02T15:05:56.000Z - 8 days ago

Fulcrum Therapeutics price target lowered to $3 from $8 at BofA

Jun 2, 2026, 6:39 AM EDT - 8 days ago

Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns

2026-06-02T10:34:23.000Z - 8 days ago

Fulcrum Therapeutics downgraded to Market Perform from Outperform at Leerink

2026-06-02T10:17:58.000Z - 8 days ago

Fulcrum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

2026-06-02T10:06:35.000Z - 8 days ago

Fulcrum Therapeutics downgraded to Market Perform from Outperform at Leerink

2026-06-02T09:15:40.000Z - 8 days ago

Fulcrum Therapeutics downgraded to Hold from Buy at Truist

2026-06-02T08:45:09.000Z - 8 days ago

Piper double downgrades Fulcrum after sickle cell development stopped

2026-06-02T00:35:47.000Z - 8 days ago

Fulcrum Therapeutics downgraded to Underweight from Overweight at Piper Sandler

2026-06-02T00:30:10.000Z - 8 days ago

Fulcrum Therapeutics downgraded to Hold from Buy at Stifel

Jun 1, 2026, 5:10 PM EDT - 8 days ago

Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns

2026-06-01T20:34:22.000Z - 8 days ago

Fulcrum discontinues pociredir program in SCD, initiates strategic review

Jun 1, 2026, 4:05 PM EDT - 8 days ago

Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review

2026-05-10T14:35:48.000Z - 4 weeks ago

Fulcrum Therapeutics price target raised to $8 from $7 at BofA

May 8, 2026, 4:30 PM EDT - 4 weeks ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Fulcrum Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Fulcrum Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 6 weeks ago

Fulcrum Therapeutics Earnings Call Transcript: Q1 2026

Apr 27, 2026, 8:00 AM EDT - 6 weeks ago

Fulcrum Therapeutics Earnings release: Q1 2026

Apr 27, 2026, 8:00 AM EDT - 6 weeks ago

Fulcrum Therapeutics Quarterly report: Q1 2026

2026-04-27T11:56:41.000Z - 6 weeks ago

Fulcrum Therapeutics reports Q1 EPS (25c), consensus (30c)

2026-04-27T11:56:23.000Z - 6 weeks ago

Fulcrum Therapeutics CFO Alan Musso to retire

Apr 27, 2026, 7:00 AM EDT - 6 weeks ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026

Apr 27, 2026, 6:55 AM EDT - 6 weeks ago

Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors

Apr 22, 2026, 7:00 AM EDT - 7 weeks ago

Fulcrum Therapeutics Slides: Corporate presentation

Apr 20, 2026, 8:00 AM EDT - 7 weeks ago

Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET

2026-03-31T17:30:41.000Z - 2 months ago

Leerink says Agios’ filing reinforces FDA flexibility ahead of Fulcrum update

AGIO

Mar 19, 2026, 8:00 AM EDT - 2 months ago

MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease

Mar 10, 2026, 1:00 PM EDT - 3 months ago

Fulcrum Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 6, 2026, 6:00 AM EST - 3 months ago

Fulcrum Therapeutics Slides: Corporate presentation

Mar 3, 2026, 8:30 AM EST - 3 months ago

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

Feb 24, 2026, 8:00 AM EST - 3 months ago

Fulcrum Therapeutics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 8:00 AM EST - 3 months ago

Fulcrum Therapeutics Annual report: Q4 2025

Feb 24, 2026, 8:00 AM EST - 3 months ago

Fulcrum Therapeutics Earnings release: Q4 2025

Feb 24, 2026, 7:01 AM EST - 3 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025

Feb 24, 2026, 7:00 AM EST - 3 months ago

Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Feb 17, 2026, 8:00 AM EST - 4 months ago

Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Jan 14, 2026, 10:30 AM EST - 5 months ago

Fulcrum Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 10, 2026, 7:00 AM EST - 5 months ago

Fulcrum Therapeutics Slides: Corporate presentation

Jan 7, 2026, 8:00 AM EST - 5 months ago

Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 10, 2025, 7:48 AM EST - 6 months ago

Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Dec 8, 2025, 4:01 PM EST - 6 months ago

Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock

Dec 7, 2025, 7:00 AM EST - 6 months ago

Fulcrum Therapeutics Transcript: Status Update

Dec 7, 2025, 7:00 AM EST - 6 months ago

Fulcrum Therapeutics Press release: Status Update

Dec 7, 2025, 7:00 AM EST - 6 months ago

Fulcrum Therapeutics Slides: Status Update

Dec 6, 2025, 5:30 PM EST - 6 months ago

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

Dec 2, 2025, 8:30 AM EST - 6 months ago

Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025

Nov 3, 2025, 4:45 PM EST - 7 months ago

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

Oct 29, 2025, 8:00 AM EDT - 8 months ago

Fulcrum Therapeutics Earnings Call Transcript: Q3 2025

Oct 29, 2025, 8:00 AM EDT - 8 months ago

Fulcrum Therapeutics Quarterly report: Q3 2025

Oct 29, 2025, 8:00 AM EDT - 8 months ago

Fulcrum Therapeutics Earnings release: Q3 2025

Oct 29, 2025, 7:00 AM EDT - 8 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025

Oct 22, 2025, 8:54 AM EDT - 8 months ago

Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET

Sep 9, 2025, 2:00 PM EDT - 9 months ago

Fulcrum Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 1:35 PM EDT - 9 months ago

Fulcrum Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 26, 2025, 8:00 AM EDT - 10 months ago

Fulcrum Therapeutics to Present at Upcoming Investor Meetings

Jul 29, 2025, 4:00 PM EDT - 11 months ago

Fulcrum Therapeutics Earnings release: Q2 2025

Jul 29, 2025, 4:00 PM EDT - 11 months ago

Fulcrum Therapeutics Quarterly report: Q2 2025

Jul 29, 2025, 6:48 AM EDT - 11 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

Jul 29, 2025, 6:45 AM EDT - 11 months ago

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Jul 28, 2025, 4:01 PM EDT - 11 months ago

Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Fulcrum Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

May 29, 2025, 4:10 PM EDT - 1 year ago

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

May 29, 2025, 8:30 AM EDT - 1 year ago

Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

May 21, 2025, 3:35 PM EDT - 1 year ago

Fulcrum Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

Fulcrum Therapeutics to Participate in Upcoming May Conferences

May 7, 2025, 8:00 AM EDT - 1 year ago

Fulcrum Therapeutics Proxy statement: Proxy Filing

May 1, 2025, 8:00 AM EDT - 1 year ago

Fulcrum Therapeutics Earnings Call Transcript: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Fulcrum Therapeutics Quarterly report: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Fulcrum Therapeutics Earnings release: Q1 2025

May 1, 2025, 7:00 AM EDT - 1 year ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Fulcrum Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Fulcrum Therapeutics Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

Mar 11, 2025, 8:40 AM EDT - 1 year ago

Fulcrum Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Feb 25, 2025, 8:00 AM EST - 1 year ago

Fulcrum Therapeutics Earnings Call Transcript: Q4 2024

Feb 25, 2025, 8:00 AM EST - 1 year ago

Fulcrum Therapeutics Annual report: Q4 2024

Feb 25, 2025, 8:00 AM EST - 1 year ago

Fulcrum Therapeutics Earnings release: Q4 2024

Feb 25, 2025, 7:00 AM EST - 1 year ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

Feb 18, 2025, 4:05 PM EST - 1 year ago

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET

Feb 12, 2025, 1:20 PM EST - 1 year ago

Fulcrum Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 6, 2025, 4:05 PM EST - 1 year ago

Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Dec 3, 2024, 12:00 PM EST - 1 year ago

Fulcrum Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 4:05 PM EST - 1 year ago

Fulcrum Therapeutics to Participate in Upcoming December Conferences

Nov 19, 2024, 3:35 PM EST - 1 year ago

Fulcrum Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 13, 2024, 8:00 AM EST - 1 year ago

Fulcrum Therapeutics Earnings Call Transcript: Q3 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

Fulcrum Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

Fulcrum Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference

Nov 6, 2024, 8:00 AM EST - 1 year ago

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

Oct 7, 2024, 2:03 PM EDT - 1 year ago

FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares

Zackpedia Jun. 10 at 3:55 PM

$FULC Down to 3.36 now, you could’ve sold when I alerted and bought back now if you wanted.

0 · Reply

Zackpedia Jun. 10 at 2:29 PM

$FULC 3.56 again!

0 · Reply

zerodayrounder Jun. 10 at 2:05 PM

$FULC someone taking small shot on July 4c? What if they already identified a reverse merge partner?

0 · Reply

Zackpedia Jun. 10 at 9:20 AM

$FULC Down to 3.38 now, you could’ve sold when I alerted and bought back now if you wanted.

1 · Reply

Zackpedia Jun. 9 at 7:39 PM

$FULC And we’re up it’s 3.58 now!

0 · Reply

Zackpedia Jun. 9 at 2:16 PM

$FULC You could’ve sold at 3.6 today!

0 · Reply

Zackpedia Jun. 8 at 7:32 PM

$FULC Down to 3.36 now where you can buy back if you want, you could’ve sold when I alerted

0 · Reply

AXLFI_HQ Jun. 7 at 4:05 PM

0 · Reply

StockScanners Jun. 6 at 10:54 PM

0 · Reply

zerodayrounder Jun. 6 at 3:04 AM

1 · Reply

Zackpedia Jun. 5 at 10:57 PM

$FULC Buy back now at 3.55 if you want

1 · Reply

XQuise Jun. 5 at 8:20 PM

$FULC 📉📈👀👈🏻😉

0 · Reply

Zackpedia Jun. 5 at 7:25 PM

$FULC Selling time at 3.68!

0 · Reply

Merlintrader Jun. 4 at 10:30 PM

$FULC Fulcrum Therapeutics (Nasdaq: $FULC): Pociredir Discontinued, Strategic Review Begins After FDA Safety Concerns https://www.merlintrader.com/fulcrum-therapeutics-strategic-review-june2026/

0 · Reply

zerodayrounder Jun. 3 at 9:31 PM

Thunder $DOMO what a nasty bar yikes Deal off ? Market is so rigged Just noticed $FULC leaked yesterday too about FDA news ... was down like 15% on huge volume then down another 50% after 8K in AH y'day.

0 · Reply

Zackpedia Jun. 3 at 3:30 PM

$FULC Selling time at 3.3!

0 · Reply

ShKumaresan Jun. 3 at 3:05 AM

$MVIS $FULC $HRTX Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? https://stocktwits.com/news-articles/markets/equity/why-did-fulc-mvis-hrtx-stocks-plunge-to-52-week-lows-today/cZ0SACPReDp

0 · Reply

StocktwitsNews Jun. 3 at 3:04 AM

Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? $FULC $HRTX $MVIS https://stocktwits.com/news/equity/markets/why-did-fulc-mvis-hrtx-stocks-plunge-to-52-week-lows-today/cZ0SACPReDp

0 · Reply

modrica3 Jun. 3 at 12:02 AM

$FULC you do realize they have $330 millions cash and no debt they could buy 10 small companies if they wanted to you dont make any sense

0 · Reply

Aglow Jun. 3 at 12:01 AM

$FULC staying far away from this stock. Who would wamt to buy this company with nithing in the pipline. Will be delisted soon

1 · Reply

BossTrade Jun. 2 at 9:52 PM

$FULC The shortbus will always take advantage of repricing cycles. They do 2-3 waves before continuation, depending on set up

0 · Reply

modrica3 Jun. 2 at 9:50 PM

$FULC i dont think it should ever fallen this low but market is full of opportunities imo gl

0 · Reply

Market Cap	229.22M
Revenue (ttm)	0.00
Net Income (ttm)	-74.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,165,062
Avg Vol	1,809,576
Day's Range	N/A - N/A
Shares Out	66.63M
Stochastic %K	16%
Beta	2.93
Analysts	Hold
Price Target	$8.70